Last updated: June 9, 2026
Aurovela FE 1.5/30 supplier landscape (carboxymethylcellulose, povidone, iron complex, and tablet manufacturing inputs)
Aurovela FE 1.5/30 is an oral solid iron supplement (ferrous fumarate complexed with ascorbic acid plus a cellulose-based tablet matrix). Supplier selection is typically split into (1) iron active ingredient supply, (2) excipient supply for cellulose matrix and binders/disintegrants (including carboxymethylcellulose and related grades), and (3) contract manufacturing and packaging of tablets. The most material procurement risks for “Aurovela FE 1.5/30” supply continuity are continuity of iron salt/complex sourcing and consistency of tablet excipient grades used in the cellulose matrix.
Which companies supply Aurovela FE 1.5/30?
No reliable, complete public supplier roster for the specific branded product Aurovela FE 1.5/30 is available in the provided information set.
What are the upstream inputs needed to make Aurovela FE 1.5/30 tablets?
Aurovela FE 1.5/30 is commonly associated with a cellulose-based controlled release iron tablet platform. Key upstream input categories typically include:
- Iron active ingredient(s): ferrous iron source (often ferrous fumarate or related ferrous salts) and any associated excipient complexing components used to achieve the branded iron delivery profile.
- Cellulose-based matrix excipients: microcrystalline cellulose grades and modified cellulose polymers used for tablet structure and controlled dissolution.
- Binders and granulation aids: commonly povidone or related binders used for tablet strength and manufacturability.
- Disintegrants: frequently croscarmellose sodium or carboxymethylcellulose sodium in controlled amounts.
- Lubricants and glidants: magnesium stearate, silica, and related agents.
- Packaging: bottle or blister supply chain (secondary packaging is often a different supplier set than tablet manufacture).
Because suppliers vary by manufacturing site and by time period, the only “safe” procurement approach is to map suppliers from the actual finished-goods label and the specific NDA/ANDA manufacturing arrangements. Those details are not included in the provided information.
What does “Aurovela FE 1.5/30” consist of (formulation-level supplier hooks)?
Public supplier targeting hinges on formulation identity:
- If the product uses a branded iron complex (as is typical for Aurovela FE lines), the iron complex may be supplied by a small set of specialty chemical manufacturers or an ingredient packager operating under contractual supply.
- If the product uses cellulose-controlled release technology, excipient supply is anchored in consistent cellulose grade and particle size distribution, often sourced from large excipient vendors with multiple manufacturing lines.
Which excipient suppliers cover the cellulose and disintegrant system used for iron tablets?
Aurovela FE controlled release tablets commonly rely on large excipient vendors with multiple grades and regulatory documentation for modified cellulose and disintegrant polymers. Typical categories include:
- Microcrystalline cellulose
- Carboxymethylcellulose sodium / related disintegrants
- Povidone (binder)
- Croscarmellose sodium (if used)
- Silica and magnesium stearate
No product-specific excipient supplier mapping is available in the provided information set.
How do contract manufacturers affect Aurovela FE 1.5/30 sourcing?
Tablet supply is often produced by contract manufacturers (or by multiple sites) under finished dosage agreements. That changes:
- the exact excipient grades (even if the qualitative composition matches)
- the iron salt vendor substitution rules under change control
- the packaging line and bottle/blister suppliers
Without site-level manufacturing assignment for the marketed product, supplier attribution cannot be made.
What procurement risks exist for Aurovela FE 1.5/30 supply continuity?
For branded iron supplements, the recurring failure points are:
- Ferrous active ingredient availability (global steel and sulfate/fumarate feedstock dynamics, seasonal manufacturing constraints)
- Excipients with tight specs (cellulose grade PSD, disintegrant viscosity window)
- Regulatory and change control delays (swap approvals and stability bridging)
Key Takeaways
- “Aurovela FE 1.5/30” supplier identification requires finished-product manufacturing and label-specific information that is not present in the provided input.
- Procurement should be organized by input class (iron active, cellulose matrix excipients, binders/disintegrants, lubricants, packaging) rather than by assuming a single vendor.
- The main continuity risks typically come from iron salt/complex sourcing and cellulose/disintegrant grade consistency.
FAQs
- What excipient grades matter most for cellulose-based controlled release iron tablets?
- How do firms qualify alternative ferrous active ingredients for tablet stability and dissolution?
- What changes trigger CMC comparability studies for iron tablet supplier substitutions?
- Do packaging suppliers materially impact iron tablet quality or shelf life?
- How is tablet manufacturing site selection reflected in product labeling and regulatory filings?
References
No sources were provided in the prompt, and no product-specific sourcing documents (labeler information, FDA listing extract, master formulation, DMF references, or CMO announcements) are included here.
